Share

January 2018; 5 (1) EditorialOpen Access

Serum neurofilament light chain in relapsing-remitting MS

Unchaining disease activity prediction?

Ruth Ann Marrie
First published November 29, 2017, DOI: https://doi.org/10.1212/NXI.0000000000000421
Full PDF
Citation
Permissions

Comment

Downloads
378

Share

Article Information

vol. 5 no. 1 e421
DOI: 
https://doi.org/10.1212/NXI.0000000000000421
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Online ISSN: 
2332-7812
History: 
  • First Published November 29, 2017.
Copyright & Usage: 
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Author Information

    1. Ruth Ann Marrie, MD, PhD
  1. Ruth Ann Marrie, MD, PhD
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. Neurology, Editorial Board Multiple Sclerosis Journal, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. Received support as site Principal Investigator for clinical trials from Sanofi- Aventis (2007-2015)

    Research Support, Government Entities:

    1. Received support as principal investigator from the Canadian Institutes of Health Research (2010-2019), and Research Manitoba (2014-2019).

    Research Support, Academic Entities:

    1. Waugh Family Chair in Multiple Sclerosis

    Research Support, Foundations and Societies:

    1. Received support as principal investigator from Multiple Sclerosis Society of Canada (2009-2016) and the National Multiple Sclerosis Society (2013-2017), and as co-principal investigator from Multiple Sclerosis Scientific Foundation (2009-2018). Received support from Consortium of Multiple Sclerosis Centers (2004-2009, 2011-2014, 2016-2017), Rx & D Health Research Foundation (2010-2015), Crohn's and Colitis Canada (2014- 2019)

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the Departments of Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Canada.
  1. Correspondence to Dr. Marrie: rmarrie{at}hsc.mb.ca
View Full Text

Article usage

Article usage: November 2017 to September 2018

AbstractFullPdfSource
Nov 20170437Highwire
Dec 2017020756Highwire
Jan 2018083683Highwire
Feb 2018015413Highwire
Mar 2018011219Highwire
Apr 20180905Highwire
Apr 2018146164pmc
May 201801139Highwire
Jun 20180839Highwire
Jun 2018104754pmc
Jul 20180586Highwire
Aug 20181435Highwire
Aug 201863542pmc
Sep 20180656Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

NOTE: All contributors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.nn.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.

  • Stay timely. Submit only on articles published within the last 8 weeks.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • 200 words maximum.
  • 5 references maximum. Reference 1 must be the article on which you are commenting.
  • 5 authors maximum. Exception: replies can include all original authors of the article.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Letters

Compose comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All contributors, besides the first/corresponding author, must complete a separate Letters Submission Form and provide via email to the editorial office before comments can be posted.

Vertical Tabs

You May Also be Interested in

Back to top

Related Articles

  • No related articles found.

Alert Me